Biologics

ISTO assumes full control of Zimmer cartilage implant

ISTO Technologies Inc. announced an agreement with Zimmer Holdings Inc. giving ISTO full control of the DeNovo ET Engineered Tissue program, an engineered cartilage implant intended to repair cartilage defects in the knee.

According to a company press release, under the terms of the agreement, any rights and responsibilities previously held by Zimmer related to ISTO and the program have been cancelled. The product has been renamed RevaFlex and will proceed independently with further development of the program though a phase 3 clinical program.

In addition, under the terms of the termination of the collaboration agreement, ISTO will transfer ownership of DeNovo NT, a particulated juvenile cartilage allograft tissue implant product, to Zimmer.

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button